Generic name: LORLATINIB 25mg
Dosage form: tablet, film coated
Medically reviewed by Drugs.com. Last updated on Jun 4, 2020.
The recommended dosage of LORBRENA is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity [see Clinical Pharmacology (12.3)].
Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if tablets are broken, cracked, or otherwise not intact.
Take LORBRENA at the same time each day. If a dose is missed, then take the missed dose unless the next dose is due within 4 hours. Do not take 2 doses at the same time to make up for a missed dose.
Do not take an additional dose if vomiting occurs after LORBRENA but continue with the next scheduled dose.
Dosage Modifications for Adverse Reactions
The recommended dose reductions are:
- First dose reduction: LORBRENA 75 mg orally once daily
- Second dose reduction: LORBRENA 50 mg orally once daily
Permanently discontinue LORBRENA in patients who are unable to tolerate 50 mg orally once daily.
Dosage modifications for adverse reactions of LORBRENA are provided in Table 1.
|Adverse Reaction*||Dosage Modifications|
|Central Nervous System Effects [see Warnings and Precautions (5.2)]|
|Grade 1||Continue at the same dose or withhold the dose until recovery to baseline. Resume LORBRENA at the same dose or at a reduced dose.|
|Grade 2 OR Grade 3||Withhold dose until Grade 0 or 1. Resume LORBRENA at a reduced dose.|
|Grade 4||Permanently discontinue LORBRENA.|
|Hyperlipidemia [see Warnings and Precautions (5.3)]|
|Grade 4 hypercholesterolemia OR
Grade 4 hypertriglyceridemia
|Withhold LORBRENA until recovery of hypercholesterolemia and/or hypertriglyceridemia to less than or equal to Grade 2. Resume LORBRENA at the same dose.
If severe hypercholesterolemia and/or hypertriglyceridemia recurs, resume LORBRENA at a reduced dose.
|Atrioventricular (AV) Block [see Warnings and Precautions (5.4)]|
|Second-degree AV block||Withhold LORBRENA until PR interval is less than 200 ms. Resume LORBRENA at a reduced dose.|
|First occurrence of complete AV block||Withhold LORBRENA until
If no pacemaker is placed, resume LORBRENA at a reduced dose.
|Recurrent complete AV block||Place pacemaker or permanently discontinue LORBRENA.|
|Interstitial Lung Disease (ILD)/Pneumonitis [see Warnings and Precautions (5.5)]|
|Any Grade treatment–related ILD/Pneumonitis||Permanently discontinue LORBRENA.|
|Other Adverse Reactions|
|Grade 1 OR Grade 2||Continue LORBRENA at same dose or reduced dose.|
|Grade 3 OR Grade 4||Withhold LORBRENA until symptoms resolve to less than or equal to Grade 2 or baseline. Resume LORBRENA at reduced dose.|
Concomitant Use of Strong or Moderate CYP3A Inducers
LORBRENA is contraindicated in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA. Avoid concomitant use of LORBRENA with moderate CYP3A inducers [see Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].
Dosage Modification for Strong CYP3A Inhibitors
Avoid concomitant use of LORBRENA with strong CYP3A inhibitors. If concomitant use with a strong CYP3A inhibitor cannot be avoided, reduce the starting dose of LORBRENA from 100 mg orally once daily to 75 mg orally once daily.
In patients who have had a dose reduction to 75 mg orally once daily due to adverse reactions and who initiate a strong CYP3A inhibitor, reduce the LORBRENA dose to 50 mg orally once daily.
If concomitant use of a strong CYP3A inhibitor is discontinued, increase the LORBRENA dose (after 3 plasma half-lives of the strong CYP3A inhibitor) to the dose that was used before starting the strong inhibitor [see Clinical Pharmacology (12.3)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Frequently Asked Questions
More about Lorbrena (lorlatinib)
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: multikinase inhibitors
- FDA Approval History